Information de reference pour ce titreAccession Number: | 00002256-199806000-00002.
|
Author: | McLeod, Howard L.
|
Institution: | Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Aberdeen
|
Title: | Clinically relevant drug-drug interactions in oncology.[Review]
|
Source: | British Journal of Clinical Pharmacology. 45(6):539-544, June 1998.
|
Abstract: | Although anticancer agents are one of the most toxic classes of medication prescribed today, there is relatively little information available about clinically relevant drug-drug interactions. Pharmacokinetic drug interactions have been described, including alterations in absorption, catabolism, and excretion. For example, an increased bioavailability of 6-mercaptopurine has been observed when combined with either allopurinol or methotrexate, leading to increased toxicity in some patients. Induction of etoposide or teniposide clearance by anticonvulsants has also been described, resulting in a lower systemic exposure and risk for lower anticancer activity. Alterations in elimination of methotrexate has been observed with probenecid, presumably through competition for renal secretion. There are also several examples of pharmacodynamic interactions. The combination of 5-fluorouracil plus folinic acid results in more efficient inhibition of thymidylate synthase, a finding which is now utilized routinely in the treatment of colorectal cancer. Improvements in the in vitro and early clinical testing now allow a relatively high degree of prediction of potential clinical drug interactions, prior to observations of untoward drug effects. In conclusion, drug interactions among commonly used anticancer agents have been identified. Their clinical significance can have more impact than many other classes of medications due to the narrow therapeutic index of antineoplastic agents and the potential for lethal side-effects. It is only through prospective, preclinical and early clinical evaluation that the presence of clinically significant drug interactions can be identified and the information used to provide better therapy for this significant health problem.
(C) 1998 Blackwell Science Ltd.
|
Author Keywords: | cancer chemotherapy; drug interactions; pharmacodynamics; pharmacokinetics.
|
References: | 1 McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 1997; 74: 39-54.
2 Calvert AH. Dose optimization of carboplatin in adults. Anticancer Res 1994; 14: 2273-2277.
3 Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12: 1667-1672.
4 van Meerten E, Verweij J, Schellens JHM. Antineoplastic agents: Drug interactions of clinical significance. Drug Safety 1995; 12: 168-182.
5 Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-339.
6 Poplack DG, Balis FM, Zimm S. The pharmacology of orally administered chemotherapy. A reappraisal. Cancer 1986; 58: 473-480.
7 Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: The price of an avoidable drug-interaction. Ann Pharmacother 1996; 30: 951-954.
8 Balis FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987; 41: 384-387.
9 Innocenti F, Danesi R, Dipaolo A, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol 1996; 37: 409-414.
10 Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs-Clinical considerations. Clin Pharmacokin 1996; 31: 470-493.
11 Baker DK, Relling MV, Pui CH, et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-315.
12 Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390-2397.
13 Grem JL, Chu E, Boarman D, et al. Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin Oncol 1992; 19, S3: 36-44.
14 Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML. Lack of effect of interferon alpha-2A upon fluorouracil pharmacokinetics. Br J Cancer 1994; 70: 724-728.
15 Swinbanks D. Deaths bring clinical trials under scrutiny in Japan. Nature 1994; 369: 697.
16 Watabe T. Strategic proposals for predicting drug-drug interactions during new drug development: Based on sixteen deaths caused by interactions of the new antiviral sorivudine with fluorouracil prodrugs. J Toxicol Sci 1996; 21: 299-300.
17 Brown MC. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy 1997; 17: 631-633.
18 Aherne GW, Piall E, Marks V, et al. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978; 1: 1097-1099.
19 Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low-dose methotrexate and probenecid. J Rheumat 1991; 18: 609-610.
20 Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997; 80: 1179-1187.
21 Baker SD. Drug interactions with the taxanes. Pharmacotherapy 1997; 17: S126-S32.
22 Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 1997; 24, S2: S85-S90.
23 Kearns CM, Egorin MJ. Considerations regarding the less than expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997; 24, S2: S91-S96.
24 Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol 1994; 13: 132.
25 McLeod HL. Clinical reversal of the multidrug resistance phenotype: True tumor modulation or pharmacokinetic interaction. Eur J Cancer 1994; 30A: 2039-2041.
26 Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
27 Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450, 3A4 and an unknown P450 enzyme. Cancer Res 1994;; 54: 4026-4035.
28 Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6-alphahydroxytaxol by human cytochrome P450, 2C8. Cancer Res 1994;; 54: 5543-5546.
29 Crespi CL, Penman BW, Gonzalez FJ, Gelboin HV, Galvin M, Langenbach R. Genetic toxicology using human cell lines expressing human P-450. Biochem Soc Trans 1993; 21: 1023-1028.
30 Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochrome P450, 2B and cytochrome; P450, 3A: in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
31 Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used-Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 1997; 32: 357-367.
32 Sobh M, Elagroudy A, Moustafa F, Harras F, Elbedewy M, Ghoneim M. Coadministration of ketoconazole to cyclosporine treated kidney transplant recipients: A prospective randomized study. Am J Nephrol 1995; 15: 493-499.
33 Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine cyclosporine prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342: 83-84.
|
Language: | English.
|
Document Type: | Reviews.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0306-5251
|
NLM Journal Code: | au9, 7503323
|
Annotation(s) | |
|
|